The Ii-Key Platform for Pandemic Preparedness Ii-
Post# of 36537
(Total Views: 334)
Posted On: 08/01/2020 5:12:30 PM
The Ii-Key Platform for Pandemic Preparedness
Ii-Key “Complete Vaccine”
For Immune System Modulation:
CD4+ Th1Response, No ADE Activation,
Neutralizing Antibody Induction, SeroConversion, Immunologic Memory
Rapid Response
1. Pathogen Identification
2. Genome Sequencing
3. Computational Vaccinology Algorithms
4. Pathogen Peptide Epitope Selection
Vaccine Development
Platform
1. Lab-scale Ii-Key-Peptide Manufacturing
2. Ex Vivo Human Trials in Convalescent Blood
1. Antibody Binding: Neutralizing & No ADE
2. T-cell response: T-Helper 1
3. Phase I/II Human Clinical Trial Protocol
Synthetic
Manufacturing at Scale
1. Standard Synthetic Peptide Manufacturing
2. Easily Scales to 100 Kg Batches
3. 100 Kg – 100 Million Vaccinations
Ii-Key “Complete Vaccine”
For Immune System Modulation:
CD4+ Th1Response, No ADE Activation,
Neutralizing Antibody Induction, SeroConversion, Immunologic Memory
Ii-Key “Complete Vaccine”
For Immune System Modulation:
CD4+ Th1Response, No ADE Activation,
Neutralizing Antibody Induction, SeroConversion, Immunologic Memory
Rapid Response
1. Pathogen Identification
2. Genome Sequencing
3. Computational Vaccinology Algorithms
4. Pathogen Peptide Epitope Selection
Vaccine Development
Platform
1. Lab-scale Ii-Key-Peptide Manufacturing
2. Ex Vivo Human Trials in Convalescent Blood
1. Antibody Binding: Neutralizing & No ADE
2. T-cell response: T-Helper 1
3. Phase I/II Human Clinical Trial Protocol
Synthetic
Manufacturing at Scale
1. Standard Synthetic Peptide Manufacturing
2. Easily Scales to 100 Kg Batches
3. 100 Kg – 100 Million Vaccinations
Ii-Key “Complete Vaccine”
For Immune System Modulation:
CD4+ Th1Response, No ADE Activation,
Neutralizing Antibody Induction, SeroConversion, Immunologic Memory
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼